DP
Therapeutic Areas
Mezzion Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Udenafil (JURVIGO®) | Improvement of exercise capacity in adolescents with Fontan physiology | Phase 3 |
Leadership Team at Mezzion Pharmaceuticals
RS
Ridwan Shabsigh, MD, FACS
President and Chief Operating Officer
JP
John Presser
EVP, Chief Business Officer